Table 3 Most frequent TEAEs (> 5% of subjects) in double-blind period up to 12 weeks
Preferred term | Placebo (N = 27) | Namilumab | ||
|---|---|---|---|---|
20 mg (N = 28) | 80 mg (N = 25) | 150 mg (N = 28) | ||
Nasopharyngitis | 5 (18.5) | 5 (17.9) | 1 (4.0) | 4 (14.3) |
Dyspnoea | 0 | 1 (3.6) | 2 (8.0) | 3 (10.7) |
Bronchitis | 2 (7.4) | 1 (3.6) | 1 (4.0) | 1 (3.6) |
Headache | 1 (3.7) | 1 (3.6) | 3 (12.0) | 0 |
Upper respiratory tract infection | 0 | 0 | 2 (8.0) | 1 (3.6) |
Rheumatoid arthritis | 0 | 2 (7.1) | 2 (8.0) | 0 |
Hypertension | 0 | 0 | 0 | 2 (7.1) |
Laryngitis | 0 | 0 | 2 (8.0) | 0 |
Menorrhagia | 0 | 2 (7.1) | 0 | 0 |
Urticaria | 0 | 2 (7.1) | 0 | 0 |